MIAMI--(BUSINESS WIRE)--Cirle, Inc., a Miami-based medical technology incubator, today announced that it will unveil its latest three-dimensional Surgical Navigation System (SNS 200) at the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles, California, May 4-8. The investigational system, for which Cirle is completing U.S. Food and Drug Administration (FDA) registration, will be on display at the Cirle booth (#1261).
“The SNS 200 is truly a next generation platform for 3-D intraoperative navigation during cataract surgery, incorporating everything we learned about surgeon needs, design priorities, systems integration, and commercial-scale manufacturing through the development and registration process of the original SNS,” said Richard Awdeh, M.D., a professor at the Bascom Palmer Eye Institute and Founder of Cirle. “The second-generation version meets all the requirements for performance and procedure optimization that we established in our first model. As a cataract surgeon, I am excited about the potential of the SNS 200 to enhance the efficiency and precision of the procedure.”
The Cirle Navigation System (SNS) is an ophthalmic image communications device which performs annotation of the source image data provided by compatible surgical microscopes. The SNS 200 incorporates smart work flow automation that increases efficiency throughout the surgery. New features of the system include:
- Digital image registration for truly marker-less tracking and guidance
- Slim-line guidance console with a minimal footprint in the surgical suite
- Smart, automated workflow
Cirle continues to focus its research programs on applications of technology and data science to improve outcomes in cataract surgery. Clinical studies designed to further characterize the advantages and importance of surgical guidance in cataract surgery are currently underway in the United States.
Established in 2010, Cirle is a medical technology incubator based in at the University of Miami Life Science and Technology Park in Miami, Fla. The company focuses on the use of translational medical research and innovative technologies to cure diseases that lead to blindness. It develops and acquires early-stage technologies, applies its specialized capabilities to refine and test them, and pursues industry collaborations to bring the technologies to market. Offering a highly interactive environment for inter-disciplinary innovation, Cirle has engaged leading eye health experts, engineers and researchers in its development projects. For more information, visit www.cirle.com.